Sublime
An inspiration engine for ideas
Dale Rhoda
@dalerhoda
Having some fun with the numbers behind $NVS's recent $87.5M acquisition of $AVRO's Cystinosis LVV gene therapy program... (1/6)
Professor Oakx.com
Investors should be honest with themselves on how hard it is to develop a drug, let alone make money from a drug
See analysis by @AtlasVentures
We try to give you the background to skew the results in your favor
#learnbiotechinvesting #biotech #investing... See more
growing crop of biotech newco's that are leveraging china preclin execution (not just CROs) coupled with US translational bio + clinical trial design
mostly working in genetic medicines, but also in ADCs and antibodies
funded by mostly non-US biotech VCs, although a couple exceptions... See more
David Lix.com
Biz_HeyGen
Michael Martinez • 1 card